Synthesis-to-Clinic®: integrating isotopic labeling and human ADME to reduce time to clinic
Pharmaceutical Technology
NOVEMBER 24, 2022
The ADME study results form an important part of the Investigational New Drug (IND) approval process in the US and for the submission of a national Clinical Trial Authorization (CTA) in the EU. This has proved to be an extremely effective option for molecules where an understanding of absolute bioavailability is required.
Let's personalize your content